Seer, Inc. Stock Price, News & Analysis

Seer, a life sciences company listed on Nasdaq under the symbol SEER, will participate in the Cowen 41^st Annual Healthcare Conference on March 3, 2021. The management will engage in a fireside chat at 8:40 a.m. PT / 11:40 a.m. ET. A live webcast will be accessible on the company’s investor website, with an archived replay available post-conference. Seer focuses on enhancing scientific outcomes through its Proteograph™ Product Suite, designed for comprehensive proteomics analysis in a short time frame.

Seer, Inc. (Nasdaq: SEER) has appointed Deep Nishar and Dr. Mostafa Ronaghi to its Board of Directors, effective February 13, 2020. Nishar, a Senior Managing Partner at SoftBank, has extensive experience in tech companies such as Google and LinkedIn. Dr. Ronaghi is a former CTO of Illumina and co-founder of Grail. Their appointments aim to enhance Seer’s leadership in the proteomics field, promoting innovative approaches to biological insights and market expansion. The company's Proteograph™ Product Suite aims to provide deep, unbiased proteomics analysis, advancing scientific outcomes.

Seer, a life sciences company, announced the closing of a public offering of 3,750,000 shares of Class A common stock at $67.00 per share, generating $251.25 million before commissions. In this offering, Seer sold 1,650,000 shares while 2,100,000 shares were sold by existing stockholders. The offering was managed by J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. The SEC approved the offering on January 27, 2021. The funds raised will be used to enhance Seer's proteomics platform, including the Proteograph Product Suite.

Seer, a life sciences company, has announced a public offering of 3,750,000 shares of Class A common stock at $67.00 per share. The offering includes 1,650,000 shares from Seer and 2,100,000 from selling stockholders. There is a 30-day option for underwriters to purchase an additional 562,500 shares. The offering is expected to close around February 1, 2021. Major investment banks involved are J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. Seer will not receive proceeds from selling stockholders' shares.

Seer, Inc. announced a proposed underwritten public offering of 3,500,000 shares of Class A common stock, with 1,400,000 shares offered by the company and 2,100,000 shares by selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 525,000 shares. Proceeds will support the commercialization and development of the Proteograph Product Suite and may also fund potential acquisitions. The offering's completion is subject to market conditions, and no assurance is given regarding timing or terms.

Seer (NASDAQ: SEER) has announced a non-exclusive commercial agreement with Thermo Fisher Scientific, enabling the integration of Thermo Fisher’s Orbitrap mass spectrometry systems with Seer’s Proteograph Product Suite. This collaboration aims to enhance end-to-end proteomics workflows, helping researchers achieve unbiased, deep proteome analysis. With both companies committed to advancing proteomics in emerging fields like proteogenomics, the combined solution will be readily available, reflecting a significant step toward expanding proteomics accessibility in various scientific markets.

Seer, a life sciences company, announced a non-exclusive agreement with Bruker Corporation to market the timsTOF Pro mass spectrometer alongside its Proteograph Product Suite. This collaboration aims to create an integrated proteomics solution that enhances accessibility for researchers. The Proteograph enables deep and rapid analysis of thousands of proteins, making it suitable for large-scale studies. Leaders from both companies emphasize the partnership’s potential to accelerate the adoption of unbiased proteomics workflows across various applications.

Seer, Inc. (Nasdaq: SEER), a life sciences company, will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:40 a.m. PT. The event will feature a presentation and Q&A session with company management. A live webcast will be accessible through the Investor section of Seer's website, with an archived replay available post-conference.

Seer focuses on delivering unbiased, rapid, and scalable proteomics information, primarily through its Proteograph™, enhancing scientific research efficiency.

Seer, a life sciences company, successfully closed its initial public offering (IPO) with 10,592,106 shares of Class A common stock priced at $19.00 per share, raising approximately $201.3 million. The IPO includes the full exercise of underwriters' options for an additional 1,381,579 shares. Seer's stock began trading on the Nasdaq under the ticker symbol SEER on December 4, 2020. The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley.